ACR 2020 - RA Highlights Brochure

0228 Impact of Upadacitinib or Adalimumab as Initial
Therapy on the Achievement of 48-Week
Treatment Goals in Patients with Rheumatoid
Arthritis and Inadequate Response to Methotrexate:
Post Hoc Analysis of a Phase 3 Study
0229 Integrated Safety of Filgotinib in Patients with
Moderately or Severely Active Rheumatoid Arthritis
Receiving Treatment for up to 5.5 Years
0234 Characterization of Serious Infections with
Upadacitinib in Patients with Rheumatoid Arthritis
0237 Safety Profile of Upadacitinib up to 3 Years of
Exposure in Patients with Rheumatoid Arthritis
0239 Adjudicated MACE and VTE in the Filgotinib RA
Program: Integrated Analysis from Phase 2 and 3
Clinical Trial
ABSTRACT SESSION • 15:00 – 15:50
Immunological Complications of Therapy
0453 Monitoring of BK Reactivation and Long-term
Safety on JAK1/2 Inhibition with Baricitinib
Saturday, November 7, 2020
POSTER SESSION B • 09:00 – 11:00
RA – Treatments Poster II: Comparative
Effectiveness, Biosimilars, Adherence &
the Real World
0808 Time to Discontinuation of Tofacitinib and TNF
Inhibitors in Rheumatoid Arthritis Patients with and
Without Methotrexate: Real World Results from a
Rheumatoid Arthritis Cohort
0813 Treatment Outcomes in Patients with Seropositive
versus Seronegative Rheumatoid Arthritis in Czech
Registry ATTRA Treated with JAK Inhibitors
0818 Efficacy and Safety of Switching Jakinibs in
Rheumatoid Arthritis
0824 The Comparative Effectiveness of Abatacept versus
Tofacitinib After 6 Months of Treatment in Patients
with RA Who Were Anti-citrullinated Protein
Antibody Positive at Baseline: Results from a US
National Observational Study
0825 Sex Differences in the Efficacy and Safety of
Tofacitinib in Rheumatoid Arthritis Patients:
A Post Hoc Analysis of Phase 3 and Long-Term
Extension Trials
0827 Comparative Clinical Efficacy of Sarilumab versus
Upadacitinib over 12 Weeks: Matching-Adjusted
Indirect Comparison Analysis
0828 Clinical and Functional Response to Tofacitinib in
Patients with Rheumatoid Arthritis: Probability Plot
Analysis of Results from a Phase 3b/4 Methotrexate
Withdrawal Study
0830 Discontinuation Rate of Tofacitinib Is Similar When
Compared to TNF Inhibitors in Rheumatoid Arthritis
Patients: Real World Results from a Rheumatoid
Arthritis Cohort
Chairman’s picks